Karam Karam , Houssein Chebbo , Sarah Saleh , Emanuel Youssef Dib , Elias Fiani , Maroun Sadek
{"title":"\"多发性骨髓瘤患者的硼替佐米肝毒性：病例报告\"","authors":"Karam Karam , Houssein Chebbo , Sarah Saleh , Emanuel Youssef Dib , Elias Fiani , Maroun Sadek","doi":"10.1016/j.hmedic.2024.100099","DOIUrl":null,"url":null,"abstract":"<div><p>We describe a case of 72-year-old female patient diagnosed with multiple myeloma (MM) in 2023, who presented with generalized fatigue. Patient was found to have elevated liver enzymes on biochemical workup. Her hepatotoxicity was attributed to Bortezomib therapy after ruling out other etiologies. Initially, patient’s liver enzymes were normal prior to Bortezomib initiation. However, her liver enzymes started trending up at day 3 during her second session of Bortezomib. Liver function tests normalized 2 weeks after discontinuing Bortezomib. This fact points to a drug-induced liver injury (DILI) whereby Bortezomib is the likely culprit. Patient was started on thalidomide-containing regimen thereafter. Her liver enzymes remained within normal range following thalidomide-based regimen.</p></div>","PeriodicalId":100908,"journal":{"name":"Medical Reports","volume":"6 ","pages":"Article 100099"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949918624000640/pdfft?md5=5dc913361d61c0bc3dcd3dd036cf41b5&pid=1-s2.0-S2949918624000640-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Bortezomib-induced hepatotoxicity in a patient with multiple myeloma: A case report\",\"authors\":\"Karam Karam , Houssein Chebbo , Sarah Saleh , Emanuel Youssef Dib , Elias Fiani , Maroun Sadek\",\"doi\":\"10.1016/j.hmedic.2024.100099\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>We describe a case of 72-year-old female patient diagnosed with multiple myeloma (MM) in 2023, who presented with generalized fatigue. Patient was found to have elevated liver enzymes on biochemical workup. Her hepatotoxicity was attributed to Bortezomib therapy after ruling out other etiologies. Initially, patient’s liver enzymes were normal prior to Bortezomib initiation. However, her liver enzymes started trending up at day 3 during her second session of Bortezomib. Liver function tests normalized 2 weeks after discontinuing Bortezomib. This fact points to a drug-induced liver injury (DILI) whereby Bortezomib is the likely culprit. Patient was started on thalidomide-containing regimen thereafter. Her liver enzymes remained within normal range following thalidomide-based regimen.</p></div>\",\"PeriodicalId\":100908,\"journal\":{\"name\":\"Medical Reports\",\"volume\":\"6 \",\"pages\":\"Article 100099\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2949918624000640/pdfft?md5=5dc913361d61c0bc3dcd3dd036cf41b5&pid=1-s2.0-S2949918624000640-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949918624000640\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949918624000640","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Bortezomib-induced hepatotoxicity in a patient with multiple myeloma: A case report
We describe a case of 72-year-old female patient diagnosed with multiple myeloma (MM) in 2023, who presented with generalized fatigue. Patient was found to have elevated liver enzymes on biochemical workup. Her hepatotoxicity was attributed to Bortezomib therapy after ruling out other etiologies. Initially, patient’s liver enzymes were normal prior to Bortezomib initiation. However, her liver enzymes started trending up at day 3 during her second session of Bortezomib. Liver function tests normalized 2 weeks after discontinuing Bortezomib. This fact points to a drug-induced liver injury (DILI) whereby Bortezomib is the likely culprit. Patient was started on thalidomide-containing regimen thereafter. Her liver enzymes remained within normal range following thalidomide-based regimen.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
